See Ovagen dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Ovagen is a short-chain peptide bioregulator derived from liver tissue, studied for its role in hepatic cell regulation and support of normal liver function. As part of the Khavinson peptide bioregulator family, it is researched in contexts of metabolic health and organ-specific peptide therapy. This data reveals the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Ovagen.
Ovagen is a short-chain peptide bioregulator targeting hepatic (liver) tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson as part of the organ-specific synthetic bioregulator program. Within the Khavinson framework — which proposes that short oligopeptides extracted from or synthesized to match sequences present in young organ tissue can exert tissue-specific epigenetic regulatory effects by binding gene promoter regions in the same tissue type — Ovagen is positioned as the liver bioregulator, derived from the parent multi-peptide hepatic extract Hepatamin / Cytomax-hepatic and chemically synthesized as a short dipeptide or tripeptide sequence representative of the liver-extracted fraction.
Ovagen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Leu) from the Khavinson family, sourced in research as a proposed liver-support peptide. It ships as a lyophilized powder reconstituted before use.
In the Khavinson framework, hepatic peptide bioregulators are proposed to act through direct binding to gene-promoter DNA in hepatocytes, selectively modulating transcription of genes involved in detoxification pathways, antioxidant defense, and bile-acid metabolism. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian single-site studies have reported Ovagen in chronic hepatic pathology, intestinal-microbiome disturbances, and immune-modulation contexts in elderly patients, with reported improvements in liver-function tests and stool-flora markers versus standard care. These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Ovagen has a reported half-life of ~few hours (bioregulator estimate), and the dose intervals researchers model most often fall around once daily (in courses). Short plasma exposure with daily dosing means no systemic buildup; like other Khavinson bioregulators it is run in short courses and its effects are thought to outlast plasma levels. It is catalogued under Anti-Aging Peptides on WPA.
6 Ovagen reconstitution calculations have been logged by the WPA community. The most common dose entered is 5mg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (6 sessions).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.